BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21765475)

  • 1. Dominant-negative mechanism of leukemogenic PAX5 fusions.
    Kawamata N; Pennella MA; Woo JL; Berk AJ; Koeffler HP
    Oncogene; 2012 Feb; 31(8):966-77. PubMed ID: 21765475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development.
    Fortschegger K; Anderl S; Denk D; Strehl S
    Mol Cancer Res; 2014 Apr; 12(4):595-606. PubMed ID: 24435167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reduced and altered activities of PAX5 are linked to the protein-protein interaction motif (coiled-coil domain) of the PAX5-PML fusion protein in t(9;15)-associated acute lymphocytic leukemia.
    Qiu JJ; Chu H; Lu X; Jiang X; Dong S
    Oncogene; 2011 Feb; 30(8):967-77. PubMed ID: 20972455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
    Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
    J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX5 fusion genes in acute lymphoblastic leukemia: A literature review.
    Fouad FM; Eid JI
    Medicine (Baltimore); 2023 May; 102(20):e33836. PubMed ID: 37335685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
    Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
    Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.
    Nebral K; König M; Harder L; Siebert R; Haas OA; Strehl S
    Br J Haematol; 2007 Oct; 139(2):269-74. PubMed ID: 17897302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia.
    Nebral K; Denk D; Attarbaschi A; König M; Mann G; Haas OA; Strehl S
    Leukemia; 2009 Jan; 23(1):134-43. PubMed ID: 19020546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ph-like acute lymphoblastic leukemia with a novel PAX5-KIDINS220 fusion transcript.
    Sakamoto K; Imamura T; Kanayama T; Yano M; Asai D; Deguchi T; Hashii Y; Tanizawa A; Ohshima Y; Kiyokawa N; Horibe K; Sato A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):278-284. PubMed ID: 27870151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
    Bousquet M; Broccardo C; Quelen C; Meggetto F; Kuhlein E; Delsol G; Dastugue N; Brousset P
    Blood; 2007 Apr; 109(8):3417-23. PubMed ID: 17179230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
    Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
    Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray.
    Kawamata N; Ogawa S; Zimmermann M; Niebuhr B; Stocking C; Sanada M; Hemminki K; Yamatomo G; Nannya Y; Koehler R; Flohr T; Miller CW; Harbott J; Ludwig WD; Stanulla M; Schrappe M; Bartram CR; Koeffler HP
    Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11921-6. PubMed ID: 18697940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer.
    An Q; Wright SL; Konn ZJ; Matheson E; Minto L; Moorman AV; Parker H; Griffiths M; Ross FM; Davies T; Hall AG; Harrison CJ; Irving JA; Strefford JC
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17050-4. PubMed ID: 18957548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case.
    Cazzaniga G; Daniotti M; Tosi S; Giudici G; Aloisi A; Pogliani E; Kearney L; Biondi A
    Cancer Res; 2001 Jun; 61(12):4666-70. PubMed ID: 11406533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.
    Okuyama K; Strid T; Kuruvilla J; Somasundaram R; Cristobal S; Smith E; Prasad M; Fioretos T; Lilljebjörn H; Soneji S; Lang S; Ungerbäck J; Sigvardsson M
    PLoS Genet; 2019 Aug; 15(8):e1008280. PubMed ID: 31381561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.
    Smeenk L; Fischer M; Jurado S; Jaritz M; Azaryan A; Werner B; Roth M; Zuber J; Stanulla M; den Boer ML; Mullighan CG; Strehl S; Busslinger M
    EMBO J; 2017 Mar; 36(6):718-735. PubMed ID: 28219927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
    Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
    Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML.
    Kurahashi S; Hayakawa F; Miyata Y; Yasuda T; Minami Y; Tsuzuki S; Abe A; Naoe T
    Oncogene; 2011 Apr; 30(15):1822-30. PubMed ID: 21217775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
    Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
    Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
    [No Abstract]   [Full Text] [Related]  

  • 20. Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.
    Hart MR; Anderson DJ; Porter CC; Neff T; Levin M; Horwitz MS
    PLoS Genet; 2018 Sep; 14(9):e1007642. PubMed ID: 30216339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.